Such findings highlight the therapeutic potential of targeting ALDH1B1 to combat CRC’s stemness and aggressiveness, proposing a novel approach to addressing the complexities of CRC treatment and management [114]. This evidence concerns the gene ALDH1B1 and colorectal carcinoma.